Valeant Psoriasis Drug ' s Suicide Risk Hard to Assess -FDA Staff Valeant Psoriasis Drug ' s Suicide Risk Hard to Assess -FDA Staff

Valeant Pharmaceuticals International Inc ' s experimental drug to treat psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, a preliminary review by the U.S. Food and Drug Administration said on Friday. < br / > < i > Reuters Health Information < /i >
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Pharmacist News Source Type: news